olmesartan + dapagliflozin

**olmesartan + dapagliflozin** is an oral bilayer combination drug formulated to improve medication compliance for patients with hypertension and type 2 diabetes. Olmesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin receptor 1, reducing blood pressure, lowering aldosterone levels, decreasing cardiac activity, and increasing sodium excretion. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor) that promotes glycosuria by blocking renal glucose reabsorption, thereby improving glycemic control in type 2 diabetes mellitus. The combination is developed to leverage synergistic effects—antihypertensive benefits and improved glycemic control—potentially providing additive protection against cardiovascular event risk, diabetic nephropathy progression, and heart failure. Clinical data support pharmacokinetic equivalence and no significant drug-drug interaction between these two agents when combined[1].

Brand names

ATB-101ATB101ATB 101

Other names

olmesartan medoxomil + dapagliflozin propanediol